VEGFA and cancer: From 2004 to 2021, at least fourteen VEGF/VEGFR2‐targeted agents (bevacizumab, ramucirumab, aflibercept, sunitinib, sorafenib, pazopanib, axitinib, regorafenib, vandetanib, nintedanib, lenvatinib, cabozantinib, fruquintinib, and tivozanib) have successfully gained regulatory approval around the world as cancer treatments in a variety of indications, including colorectal, lung, breast, renal, brain, ovarian, cervical, hepatic, and thyroid carcinomas, as well as pancreatic neuroendocrine tumors and soft‐tissue sarcomas (Shirley, 2018; Zirlik & Duyster, 2018).